RAPID3, an Index to Assess and Monitor Patients with Rheumatoid Arthritis, Without Formal Joint Counts: Similar Results to DAS28 and CDAI in Clinical Trials and Clinical Care

Rheumatic Disease Clinics of North America

Volumn 35, Issue 4, 2009, Pages 773-778

  Pincus, Theodore ^a   Yazici, Yusuf ^a   Bergman, Martin J ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Taylor Hospital   (United States)

Author keywords

CDAI; DAS28; RAPID3 (routine assessment of patient index data 3); Rheumatoid arthritis (RA)

Indexed keywords

ABATACEPT; ADALIMUMAB; C REACTIVE PROTEIN; LEFLUNOMIDE; METHOTREXATE;

CLINICAL DECISION MAKING; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE SEVERITY; DRUG RESPONSE; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAPID3; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SELF REPORT; SENSITIVITY AND SPECIFICITY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; DISABILITY EVALUATION; DRUG MONITORING; HEALTH STATUS; HUMANS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 70749145562     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2009.10.008     Document Type: Review

References (13)

1. Pincus T., Swearingen C.J., Bergman M., et al. RAPID3 (routine assessment of patient index data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to DAS and CDAI categories. J Rheumatol 35 (2008) 2136-2147
2. Saag K.G., Teng G.G., Patkar N.M., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59 (2008) 762-784
3. van der Heijde D.M., van't Hof M., van Riel P.L., et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 20 (1993) 579-581
4. Prevoo M.L., van't Hof M.A., Kuper H.H., et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38 (1995) 44-48
5. Aletaha D., and Smolen J. The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23 (2005) S100-S108
6. Stucki G., Liang M.H., Stucki S., et al. A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Arthritis Rheum 38 (1995) 795-798
7. Wolfe F., Michaud K., and Pincus T. A composite disease activity scale for clinical practice, observational studies and clinical trials: the patient activity scale (PAS/PAS-II). J Rheumatol 32 (2005) 2410-2415
8. Yazici Y., Bergman M., and Pincus T. Time to score quantitative rheumatoid arthritis measures: 28-joint count, disease activity score, health assessment questionnaire (HAQ), multidimensional HAQ (MDHAQ), and routine assessment of patient index data (RAPID) scores. J Rheumatol 35 (2008) 603-609
9. Pincus T, Swearingen CJ, Bergman MJ, et al. RAPID3 on an MDHAQ is correlated significantly with activity levels of DAS28 and CDAI, but scored in 5 versus more than 90 seconds. Arthritis Care Res, in press.
10. Pincus T., Bergman M.J., Yazici Y., et al. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures. Rheumatology (Oxford) 47 (2008) 345-349
11. Pincus T., Strand V., Koch G., et al. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the disease activity score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum 48 (2003) 625-630
12. Pincus T., Chung C., Segurado O.G., et al. An index of patient self-reported outcomes (PRO index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. J Rheumatol 33 (2006) 2146-2152
13. Neogi T., Felson D., Niu J., et al. The association between radiographic features of knee osteoarthritis and pain: results from two cohort studies. BMJ (2009, Aug 21) [Epub ahead of print]